Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced its participation in four major upcoming investor conferences in February and March 2025:
• H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Fireside chat on February 25 at 1:30 PM ET
• TD Cowen 45th Annual Health Care Conference - Company presentation in Boston on March 3 at 11:50 AM ET
• Barclays 27th Annual Global Healthcare Conference - Fireside chat in Miami on March 11 at 8:30 AM ET
• Leerink Partners Global Healthcare Conference - Fireside chat in Miami on March 12 at 11:20 AM ET
Live webcasts of the presentations, when available, can be accessed through the Investors section of Fate Therapeutics' website under 'Events & Presentations,' with archived recordings available shortly after each event.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC per il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori in programma a febbraio e marzo 2025:
• 3ª Conferenza Virtuale Annuale sulla Terapia Cellulare H.C. Wainwright - Conversazione informale il 25 febbraio alle 13:30 ET
• 45ª Conferenza Annuale sulla Salute TD Cowen - Presentazione dell'azienda a Boston il 3 marzo alle 11:50 ET
• 27ª Conferenza Annuale Globale sulla Salute Barclays - Conversazione informale a Miami l'11 marzo alle 8:30 ET
• Conferenza Globale sulla Salute di Leerink Partners - Conversazione informale a Miami il 12 marzo alle 11:20 ET
Le trasmissioni in diretta delle presentazioni, quando disponibili, possono essere accessibili nella sezione Investitori del sito web di Fate Therapeutics sotto 'Eventi e Presentazioni', con registrazioni archiviate disponibili poco dopo ogni evento.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica centrada en terapias inmunológicas celulares derivadas de iPSC para el cáncer y enfermedades autoinmunes, ha anunciado su participación en cuatro importantes conferencias para inversores que se llevarán a cabo en febrero y marzo de 2025:
• 3ª Conferencia Virtual Anual sobre Terapia Celular H.C. Wainwright - Charla informal el 25 de febrero a la 1:30 PM ET
• 45ª Conferencia Anual de Salud TD Cowen - Presentación de la empresa en Boston el 3 de marzo a las 11:50 AM ET
• 27ª Conferencia Anual Global de Salud Barclays - Charla informal en Miami el 11 de marzo a las 8:30 AM ET
• Conferencia Global de Salud de Leerink Partners - Charla informal en Miami el 12 de marzo a las 11:20 AM ET
Las transmisiones en vivo de las presentaciones, cuando estén disponibles, se podrán acceder a través de la sección de Inversores en el sitio web de Fate Therapeutics bajo 'Eventos y Presentaciones', con grabaciones archivadas disponibles poco después de cada evento.
페이트 테라퓨틱스 (NASDAQ: FATE)는 암과 자가면역 질환을 위한 iPSC 유래 세포 면역 요법에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 2월과 3월에 열리는 네 가지 주요 투자자 회의에 참여할 것이라고 발표했습니다:
• H.C. 웨인라이트 제3회 연례 세포 치료 가상 회의 - 2월 25일 오후 1시 30분 ET에 진행되는 대화
• TD 코웬 제45회 연례 헬스케어 회의 - 3월 3일 오전 11시 50분 ET에 보스턴에서 회사 발표
• 바클레이스 제27회 연례 글로벌 헬스케어 회의 - 3월 11일 오전 8시 30분 ET에 마이애미에서 대화
• 리어링크 파트너스 글로벌 헬스케어 회의 - 3월 12일 오전 11시 20분 ET에 마이애미에서 대화
발표의 실시간 웹캐스트는 Fate Therapeutics 웹사이트의 투자자 섹션에서 '이벤트 및 발표' 아래에서 확인할 수 있으며, 각 이벤트 후에 아카이브된 녹화도 제공됩니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique axée sur les immunothérapies cellulaires dérivées d’iPSC pour le cancer et les maladies auto-immunes, a annoncé sa participation à quatre importantes conférences d’investisseurs à venir en février et mars 2025 :
• 3ème Conférence Virtuelle Annuelle sur la Thérapie Cellulaire H.C. Wainwright - Discussion informelle le 25 février à 13h30 ET
• 45ème Conférence Annuelle sur la Santé TD Cowen - Présentation de l’entreprise à Boston le 3 mars à 11h50 ET
• 27ème Conférence Annuelle Mondiale sur la Santé Barclays - Discussion informelle à Miami le 11 mars à 8h30 ET
• Conférence Mondiale sur la Santé de Leerink Partners - Discussion informelle à Miami le 12 mars à 11h20 ET
Les webcasts en direct des présentations, lorsque disponibles, peuvent être consultés dans la section Investisseurs du site de Fate Therapeutics sous 'Événements et Présentations', avec des enregistrements archivés disponibles peu après chaque événement.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien für Krebs und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im Februar und März 2025 bekannt gegeben:
• 3. Virtuelle Jahreskonferenz zur Zelltherapie H.C. Wainwright - Gespräch am 25. Februar um 13:30 Uhr ET
• 45. Jährliche Gesundheitskonferenz TD Cowen - Unternehmenspräsentation in Boston am 3. März um 11:50 Uhr ET
• 27. Jährliche Globale Gesundheitskonferenz Barclays - Gespräch in Miami am 11. März um 8:30 Uhr ET
• Globale Gesundheitskonferenz von Leerink Partners - Gespräch in Miami am 12. März um 11:20 Uhr ET
Die Live-Webcasts der Präsentationen, wenn verfügbar, können im Investorenbereich der Website von Fate Therapeutics unter 'Veranstaltungen & Präsentationen' abgerufen werden, mit archivierten Aufzeichnungen, die kurz nach jeder Veranstaltung verfügbar sind.
- None.
- None.
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, including a fireside chat at 1:30 PM ET on Tuesday, February 25, 2025
- TD Cowen 45th Annual Health Care Conference, including a company presentation at 11:50 AM ET on Monday, March 3, 2025 in Boston, Massachusetts
- Barclays 27th Annual Global Healthcare Conference, including a fireside chat at 8:30 AM ET on Tuesday, March 11, 2025 in Miami, Florida
- Leerink Partners Global Healthcare Conference, including a fireside chat at 11:20 AM ET on Wednesday, March 12, 2025 in Miami, Florida
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
What investor conferences will Fate Therapeutics (FATE) attend in early 2025?
How can investors access Fate Therapeutics' conference presentations in 2025?
What types of therapeutic developments will FATE discuss at the 2025 conferences?
Where will Fate Therapeutics' in-person conference presentations take place in March 2025?
